{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:15:50Z","timestamp":1788279350684,"version":"build-2803163510"},"reference-count":18,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 annual meeting, held in Bogot\u00e1, Colombia, featured soapbox presentations highlighting innovative approaches to psoriatic disease (PsD) care. Dr. Vasileios Charisis presented the Psoriatic Arthritis Inflammation Explained Through Multi-Source Data Analysis Guiding a Novel Personalised Digital Care Ecosystem (iPROLEPSIS) project, which applies digital phenotyping and explainable artificial intelligence to monitor psoriatic arthritis (PsA) using smartphone-based typing dynamics and hand motion tracking. Pilot data demonstrated high accuracy in detecting functional impairments, underscoring the potential of digital biomarkers for personalized disease management. Dr. Rodrigo Garc\u00eda-Salinas reported consensus recommendations from the Red de Excelenciaen Artritis para la Am\u00e9rica Latina\u2013Pan American League of Associations for Rheumatology (REAL-PANLAR) group to establish PsD Centers of Excellence (CoEs) in Latin America. Through a Delphi process, experts from 12 countries defined structural, process, and outcome standards, resulting in 2 adaptable models\u2014optimal and model\u2014designed to reduce diagnostic delays, enhance multidisciplinary collaboration, and improve outcomes. Dr. Juan Raul Castro-Ayarza summarized real-world evidence on biologic drug survival in Latin America, emphasizing fragmented data and variability across national cohorts. Findings from Venezuela, Brazil, Argentina, and Colombia revealed differences in treatment persistence and predictors of discontinuation, reinforcing the need for a standardized regional registry. Collectively, these initiatives demonstrate the value of digital health tools, region-specific care frameworks, and real-world evidence in advancing PsD management globally.<\/jats:p>","DOI":"10.3899\/jrheum.2026-0371","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:20:31Z","timestamp":1778847631000},"page":"23-27","source":"Crossref","is-referenced-by-count":0,"title":["Transforming Psoriatic Disease Care Through Innovation and Real-World Data: GRAPPA 2025 Soapbox Highlights"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-8384","authenticated-orcid":false,"given":"Keith","family":"Colaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-2684","authenticated-orcid":false,"given":"Juan Raul","family":"Castro-Ayarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-2343","authenticated-orcid":false,"given":"Vasileios","family":"Charisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5928-1092","authenticated-orcid":false,"given":"Rodrigo","family":"Garc\u00eda-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026090108201043000_53.Suppl_2.23.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11295"},{"key":"2026090108201043000_53.Suppl_2.23.2","unstructured":"iPROLEPSIS . iPROLEPSIS is a solution for psoriatic arthritis. [Internet. Accessed April 6, 2026.] Available from: https:\/\/www.iprolepsis.eu"},{"key":"2026090108201043000_53.Suppl_2.23.3","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.1038\/s41598-020-69369-1","article-title":"Screening of Parkinsonian subtle fine-motor impairment from touchscreen typing via deep learning","volume":"10","author":"Iakovakis","year":"2020","journal-title":"Sci Rep"},{"key":"2026090108201043000_53.Suppl_2.23.4","doi-asserted-by":"publisher","DOI":"10.2196\/37614"},{"key":"2026090108201043000_53.Suppl_2.23.5","unstructured":"Google . Google AI for developers: hand landmark detection guide. [Internet. Accessed April 10, 2026.] Available from: https:\/\/ai.google.dev\/edge\/mediapipe\/solutions\/vision\/hand_landmarker"},{"key":"2026090108201043000_53.Suppl_2.23.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03574.x"},{"key":"2026090108201043000_53.Suppl_2.23.7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-023-06838-8","article-title":"Burden of disease in psoriatic arthritis in Latin America: a systematic literature review","volume":"43","author":"Bautista-Molano","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026090108201043000_53.Suppl_2.23.8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/RHU.0000000000000247","article-title":"REAL-PANLAR project for the implementation and accreditation of centers of excellence in rheumatoid arthritis throughout Latin America: a consensus position paper from REAL-PANLAR group on improvement of rheumatoid arthritis care in Latin America establishing centers of excellence","volume":"21","author":"Santos-Moreno","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"2026090108201043000_53.Suppl_2.23.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2026090108201043000_53.Suppl_2.23.10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00296-018-3986-4","article-title":"Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain","volume":"38","author":"Gratac\u00f3s","year":"2018","journal-title":"Rheumatol Int"},{"key":"2026090108201043000_53.Suppl_2.23.11","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/jdv.14393","article-title":"Psoriasis in Latin America and the Caribbean: a systematic review","volume":"31","author":"Hern\u00e1ndez-V\u00e1squez","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026090108201043000_53.Suppl_2.23.12","doi-asserted-by":"crossref","first-page":"e8064","DOI":"10.5867\/medwave.2020.10.8064","article-title":"Clinical and epidemiological characterization of patients with psoriasis and the prescription of biological therapy in Venezuela: a cross-sectional study","volume":"20","author":"Rojano Rada","year":"2020","journal-title":"Medwave"},{"key":"2026090108201043000_53.Suppl_2.23.13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.abd.2020.08.011","article-title":"Survival of immunobiological drugs in psoriasis: preliminary data from a tertiary hospital experience in Southern Brazil","volume":"96","author":"Lima","year":"2021","journal-title":"An Bras Dermatol"},{"key":"2026090108201043000_53.Suppl_2.23.14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.abd.2023.03.002","article-title":"Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study","volume":"99","author":"Alves","year":"2024","journal-title":"An Bras Dermatol"},{"key":"2026090108201043000_53.Suppl_2.23.15","doi-asserted-by":"crossref","first-page":"ljae360.127","DOI":"10.1093\/bjd\/ljae360.127","article-title":"P97 Drug survival rates and predictors of switching in psoriasis: a study of biologics and small molecules in the Argentine population [abstract]","volume":"191","author":"Cura","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026090108201043000_53.Suppl_2.23.16","unstructured":"Castro Ayarza JR. [Persistence of biological therapy in a cohort of patients diagnosed with psoriasis at a specialized center in Colombia.] [Article in Spanish] Universidad de los Andes. [Internet. Accessed April 10, 2026.] Available from: https:\/\/hdl.handle.net\/1992\/73173"},{"key":"2026090108201043000_53.Suppl_2.23.17","unstructured":"Castro Ayarza JR , Toloza-Perez Y , Becerra-Arias C , Donado J , Zapata ND. Absolute risk of therapeutic failure or adverse drug reactions associated with guselkumab or risankizumab [abstract]. Presented at: SPIN Congress; 2025 July 2-4; Paris, France."},{"key":"2026090108201043000_53.Suppl_2.23.18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21615\/cesmedicina.6335","article-title":"[Clinical, sociodemographic, pharmacological characterization and quality of life of patients diagnosed with moderate-to-severe psoriasis treated at a specialized psoriasis clinic]","volume":"36","author":"Mesa","year":"2022","journal-title":"CES Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2026-0371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:20:18Z","timestamp":1788276018000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2026-0371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":18,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.3899\/jrheum.2026-0371"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2026-0371","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}